ZYCLARA
Zyclara est indiqué pour le traitement local des kératoses actiniques (KA) cliniquement typiques, non hyperkératosiques, …
Additional information from the official database
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
37.5 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
20.0 MG | Substance | HBESI |
|
(N/A)
|
22.0 MG | Substance | HBESI |
|
(N/A)
|
31.0 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
2.0 MG | Substance | HBESI |
|
(N/A)
|
0.2 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
6312 Steinhausen